We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microbiota’s Role Explored in Colorectal Cancer Among the Young

By LabMedica International staff writers
Posted on 06 Feb 2020
Colorectal cancer incidence has been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous.

However such screenings are generally not recommended for people under age 50, but colorectal cancer rates have been increasing at nearly a 2% annual rate in people under age 55 since 2006. More...
There are many theories about why, including a rise in obesity, diabetes, and diets low in whole grains among younger people.

Bacteria typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body's microbiome could affect cancer outcomes to varying degrees.

Oncologists at the Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA) analyzed the role of the microbiome in colorectal cancer. To do this they looked at the DNA and microbiome of archived tumors, as well as adjacent normal tissue when available, from 31 patients with colorectal cancer who were diagnosed before the age of 45 or after the age of 65.

Scientists have known that certain microbes that comprise the microbiome, which consists of different types of bacteria, fungi and viruses, can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Scientists also know that F. nucleatum can promote cancerous growth by suppressing immune responses in the colon.

Overall, the investigators found 478 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nucleatum, which appeared in five of the younger patients' tumors and in three of the older patients' tumors. The team also found a significant difference in the rate of Moraxella osloensis (11% versus 46%) in younger compared to older patients.

Benjamin Adam Weinberg, MD, an assistant professor of medicine and a senior author of the study, said, “There was a much higher presence of F. nucleatum in younger patients than we expected. We haven't seen large genetic differences in colorectal tumors from younger versus older people, so we hypothesize that something else, perhaps the microbiome, is contributing to the rise in incidence of the disease in younger people.” The study was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium held January 23-25, 2020 in San Francisco, CA, USA).

Related Links:
Georgetown Lombardi Comprehensive Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dr. Maria “Ken” Figueroa is investigating how epigenetics can inform treatment paths for cancer patients. (Image Credit: Sylvester Comprehensive Cancer Center)

DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Melioidosis is a serious, sometimes fatal infection caused by Burkholderia pseudomallei, a bacterium found in tropical and subtropical soil and surface water. (Image Credit: Adobe Stock)

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.